5 stories
Generics coverage on Peptide News Digest tracks GLP-1 patent expiries, licensed-generic launches, biosimilar pathways, and the cost dynamics that follow them.
The most consequential 2026 move: India's semaglutide patent expired in March, and Biocon, Dr. Reddy's, and other domestic manufacturers brought licensed generics to retail within weeks. Apotex has covered the Canadian generic market. The biosimilar pathway for peptide drugs continues to be debated in FDA and EMA guidance — semaglutide's complex synthesis and the difference between true biosimilars and follow-on small-molecule peptides matters for the long-term cost curve.
Stories here cover the launches, the patent litigation, and the price implications. See #india for the Indian market specifically and #pricing for the broader cost context.
CNBC reports Eli Lilly's Indian GLP-1 market share fell from 61% to 56% in March as 26 generic semaglutide brands from 13 companies entered the market following patent expiry. Novo Nordisk held steady at 25% after slashing Ozempic prices 38% and Wegovy prices 48%, while Lilly's Mounjaro remains priced 10x above the cheapest generics.
Tirzepatide (Mounjaro) Indian sales fell to ₹114 crore in March from ₹135 crore in February, while semaglutide sales rose to ₹59 crore. Semaglutide's GLP-1 segment share jumped to 33% from 25% as dozens of generics flood the market.
India's drug regulators are intensifying GLP-1 oversight ahead of semaglutide's patent expiry. The Drug Controller General audited 49 entities and issued notices to violators.
Following Novo Nordisk's patent expiry on March 20, more than 50 generic semaglutide versions are anticipated in India, dramatically expanding GLP-1 access.
Biocon's incoming CEO said the company will prioritize Canada, Brazil, and the Middle East instead of India's saturated GLP-1 market with 40+ generic entrants.